Introduction: In 2020, Dr. Eric Lenze and his team launched a pilot study to explore how ketamine might help older […]
Introduction: In 2019, the FDA approved esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). This report by
Introduction: The FDA reviewed a new treatment called esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). TRD
Introduction: Ketamine and esketamine are increasingly investigated for their potential in managing TRD. This systematic review examines clinical trials registered
Introduction: Ketamine and esketamine have been explored in medical research for treating treatment-resistant depression (TRD), a severe form of depression
Introduction:The 2017 consensus statement by the APA Council of Research Task Force on Novel Biomarkers and Treatments, led by Sanacora
Introduction:A groundbreaking 2017 report by the American Psychiatric Association (APA) sheds light on the use of ketamine to treat mood
Introduction:A 2023 study published in Epilepsia Open by Dr. Gaston and colleagues examined how cannabidiol (CBD) interacts with common seizure
If you’re exploring new treatments for depression, anxiety, or PTSD, you may have heard about ketamine therapy—a unique approach that’s
None of the statements in this announcement or via any web sites linked herein have been evaluated by the FDA. Furthermore, none of the statements in this announcement or any web sites linked herein should be construed as dispensing medical advice or making claims regarding the cure of diseases. You should consult a licensed health care professional before starting any supplement, dietary, or exercise program, especially if you are pregnant or have any pre-existing injuries or medical conditions. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any diseases.
